

# Exploring Different Contexts of Statin Deprescribing: A Vignette-Based Experiment with Older Adults Across Four Countries



J Gen Intern Med  
DOI: 10.1007/s11606-024-08698-7  
© The Author(s) 2024

## BACKGROUND

Deprescribing is the process of a healthcare professional reducing or stopping an inappropriate medication.<sup>1</sup> Statins, commonly prescribed to prevent cardiovascular events, pose uncertain benefits and potential harms for older adults, making deprescribing a preference-sensitive decision.<sup>2,3</sup>

Deprescribing studies typically ask general questions about deprescribing preferences; however, clinicians may need to consider contextual factors specific to the individual patient when making a deprescribing recommendation. This study aimed to test the impact of contextual factors on older persons' agreement with a statin deprescribing recommendation.

## METHODS

The details of our research paradigm have been described elsewhere.<sup>4</sup> A vignette-based online experiment was conducted with older people from Australia, the Netherlands,

United Kingdom, and United States. The study was registered at ClinicalTrials.gov Identifier: NCT04676282 and received exempt status approval from the University of Michigan Institutional Review Board.

Participants 65 years and older were recruited through a panel of Internet users administered by Qualtrics Research Panels (Provo, UT) in autumn 2021. Sampling quotas were employed to ensure roughly equal representation by country and gender with a total target of 1200 participants per country. Vignettes involving a hypothetical patient with polypharmacy (Mrs. EF) were identical except for randomization to one of six contextual factors (Box 1). The primary outcome was agreement with the deprescribing recommendation: "I think that Mrs. EF should follow her PCP's recommendation and stop taking the simvastatin" on a 6-point Likert scale, with "Strongly disagree (1)" and "Strongly agree (6)" as the scale anchors. The survey was administered in Dutch for the Netherlands.

---

*Kristie Rebecca Weir and Sarah E. Vordenberg share first authorship.*

---

**Trial Registration:** *ClinicalTrials.gov Identifier NCT04676282.*


---

*Received November 14, 2023*

*Accepted February 23, 2024*

Published online: 21 March 2024

**Box 1 Summary of Manipulations Conducted in the Experimental Survey (Contextual Factor Manipulations in Bold)**<sup>a</sup>

Name	Paragraph 1	Paragraph 2	Conversation
Control	Mrs. EF <sup>b</sup> has regularly seen her PCP <sup>c</sup> for the past 10 years to help manage her health. A PCP is a doctor, nurse practitioner, or physician assistant who sees people for common medication conditions. She trusts per PCP.	Mrs. EF's husband was diagnosed with cancer several years ago and he recently had a stroke. She has been very busy taking care of him which has made it more difficult for her to manage her health conditions through lifestyle choices, such as eating healthy foods and being physically active.	PCP: "I was looking at your list of medicines and I would like to talk with you about potentially stopping your simvastatin." Patient: "I am surprised that you are recommending stopping it." Patient: "When I started the medicine, you told me I was going to take it for the rest of my life to lower my cholesterol and help prevent me from having a stroke." [sentence that was manipulated] PCP: "When you first started to take the medicine, it made sense for you. However, you have never had a stroke and as people get older, simvastatin may not provide as much benefit and could lead to more side effects. This is why I recommend that you stop taking simvastatin."
Specialist prescriber	<b>Control + For many years she also saw a cardiologist who prescribed the medicine, simvastatin, for her heart problems. Her cardiologist recently retired and now she only receives care from her PCP.</b>	Control	Patient: "When I started the medicine, <b>my cardiologist</b> told me I was going to take it for the rest of my life to lower my cholesterol and help prevent me from having a stroke."
Family influence	Control	<b>Mrs. EF's adult daughter always checks to make sure that Mrs. EF takes her simvastatin to help her maintain her health.</b>	Patient: "When I started the medicine, <b>you told my daughter and me</b> that I was going to take it for the rest of my life to lower my cholesterol and help prevent me from having a stroke."
Spouse stroke	Control	<b>After he stopped taking simvastatin based on the advice of his PCP, he had a stroke.</b>	Patient: "When I started the medicine, you told me I was going to take it for the rest of my life to lower my cholesterol and help prevent me from having a stroke, <b>especially considering my husband's experience.</b> "
Stroke image	<b>Control + While she is in the waiting room, she sees this image of a poster about strokes.</b> 	Control	Control
Lifestyle change difficulty <sup>d</sup>	Control	<b>Even before she was taking care of her husband, she had problems exercising and eating healthier foods.</b>	Patient: "When I started the medicine, you told me I was going to take it for the rest of my life to lower my cholesterol and help prevent me from having a stroke, <b>especially since I have a hard time exercising and eating healthier foods.</b> "

<sup>a</sup>All manipulations included the information from the control vignette as well, unless otherwise noted

<sup>b</sup>Mrs EF is a 76-year-old patient taking 11 medications to manage multiple health condition

<sup>c</sup>Primary care provider


<sup>d</sup>Lifestyle change difficulty vignette was motivated by the potential difficulty to lower one's cholesterol through lifestyle changes alone

We calculated the mean agreement with stopping the simvastatin by contextual factor. We conducted a three-way ANOVA with Bonferroni-corrected post hoc comparisons to test for differences by contextual factor. We used a statistical significance level of  $p < 0.05$ . All analyses were conducted with Stata SE 17.0 (StataCorp).

**RESULTS**

The final analytical sample was 4873 participants (93.2% completion rate among eligible participants).

Participants were a mean age of 71.5 years (standard deviation (SD) 5.1 years), 48.6% were female, and 33.7% had an



<sup>a</sup> Values sharing the same superscript letter are significantly different from each other

<sup>b</sup> 6-point Likert scale with scale anchors "Strongly disagree (1)" and "Strongly agree (6)"

**Figure 1 Mean participant agreement scores<sup>a</sup> for stopping simvastatin by contextual factor with standard error bars (n = 4873)<sup>b</sup>**

education level of high school or less. The mean number of medications taken by participants was 7.1 (SD = 10.5).

The overall mean level of agreement for stopping simvastatin was high (4.50 out of 6, SD = 1.42), with significant differences across contextual factors (Fig. 1). Compared to the control vignette (mean = 4.69), agreement with the deprescribing recommendation was significantly lower in the spouse stroke (mean = 4.20,  $p < 0.001$ ), specialist prescriber (mean = 4.31,  $p < 0.001$ ), and stroke image (mean = 4.45,  $p < 0.05$ ) vignettes.

## DISCUSSION

Consistent with our previous vignette-based experiment,<sup>4</sup> we found high acceptance of a statin deprescribing recommendation among older adults. Participants had significantly lower agreement when the statins were originally prescribed by a cardiologist, when the hypothetical patient's spouse had a stroke after stopping statin, and after viewing a poster visually displaying how a stroke occurs, compared to participants receiving no additional contextual information (control condition). The use of vignettes may under-estimate the effects of these types of factors as it is likely that people have stronger emotional responses to these types of situations in real life.

Previous research has shown that older adults and primary care practitioners are more hesitant to stop a medication that was initially prescribed by a specialist.<sup>5,6</sup> While multiple prescribers may be necessary to ensure patients receive optimal care across multiple conditions, it can increase the complexity of engaging in deprescribing conversations.<sup>7</sup>

The vignettes in which the spouse had a stroke or the participant viewed an image showing what occurs during a stroke may have evoked an emotional response from participants. More research is needed regarding the influence of emotions (e.g., fear, worry, disgust) on deprescribing attitudes and decisions.

This study is limited by being an online experiment focused on simvastatin; it is not clear if our findings generalize to other preventive medications (antiplatelets or antihypertensives, for example).


This study provides evidence that different contextual factors can influence how patients think about statin deprescribing decisions. Clinicians should consider how a statin was started, in what setting, and by whom, as well as external factors that may increase patient concern when engaging in deprescribing conversations with patients.

**Funding** Open Access funding enabled and organized by CAUL and its Member Institutions.

**Data Availability** The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

## Declarations:

**Conflict of Interest:** The authors declare that they do not have a conflict of interest.

Kristie Rebecca Weir, PhD<sup>1,2</sup>   
 Sarah E. Vordenberg, MPH<sup>3</sup>  
 Aaron M. Scherer, PhD<sup>4</sup>  
 Jesse Jansen, PhD<sup>5</sup>  
 Nancy Schoenborn, MHS, PhD<sup>6</sup>  
 Adam Todd, PhD<sup>7</sup>

<sup>1</sup>Sydney School of Public Health, Menzies Centre for Health Policy & Economics, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia;

<sup>2</sup>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland;

<sup>3</sup>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA;

<sup>4</sup>University of Iowa Carver College of Medicine, Iowa City, IA, USA;

<sup>5</sup>Department of Family Medicine, Care and Public Health Research Institute (CAHRI), Faculty of Health Medicine and Life Sciences (FHML) Maastricht University, Maastricht, the Netherlands;

<sup>6</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA;

<sup>7</sup>Newcastle University School of Pharmacy, Newcastle upon Tyne, UK

**Corresponding Author:** Kristie Rebecca Weir, PhD; Sydney School of Public Health, Menzies Centre for Health Policy & Economics, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia (e-mail: Kristie.weir@sydney.edu.au).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## REFERENCES

1. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. *JAMA Intern Med.* 2015;175(5):827-834.
2. Thompson W, Pottgård A, Nielsen JB, Haastруп P, Jarbøl DE. How common is statin use in the oldest old? *Drugs Aging.* 2018;35:679-686.
3. van Middelaar T, van Charante EPM. Deprescribing preventive medication in older patients. *Br J Gen Pract.* 68(675), 456-457.
4. Vordenberg SE, Weir KR, Jansen J, Todd A, Schoenborn N, Scherer AM. Harm and medication-type impact agreement with hypothetical

- deprescribing recommendations: a vignette-based experiment with older adults across four countries. *J Gen Intern Med.* 2023;38(6):1439-1448. <https://doi.org/10.1007/s11606-022-07850-5>
5. **Goyal P, Requijo T, Siceloff B, et al.** Patient-Reported Barriers and Facilitators to Deprescribing Cardiovascular Medications. *Drugs Aging.* 2020;37(2):125-135. <https://doi.org/10.1007/s40266-019-00729-x>
  6. **Anderson K, Stowasser D, Freeman C, Scott I.** Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. *BMJ Open.* 2014;4(12):e006544.
  7. **Almodovar AS, Keller MS, Lee J, Mehta HB, Manja V, Nguyen TPP et al.** Deprescribing medications among patients with multiple prescribers: A socioecological model. *J Am Geriatr Soc.* 2023;11(9). <https://doi.org/10.1111/jgs.18667>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.